Advances in the treatment of macular corneal dystrophy
10.3980/j.issn.1672-5123.2019.11.12
- VernacularTitle:斑状角膜营养不良治疗的研究进展
- Author:
Wen-Qing Shi
1
Author Information
1. Department of Ophthalmology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China
- Publication Type:Journal Article
- Keywords:
macular corneal dystrophy;
CHST6;
penetrating keratoplasty
- From:
International Eye Science
2019;19(11):1870-1873
- CountryChina
- Language:Chinese
-
Abstract:
Macular corneal dystrophy(MCD)refers to corneal stromal dystrophy, which can cause progressive visual field defects. MCD belongs to autosomal recessive disease. Mutation of CHST 6 gene is considered to be a pathogenic factor. In general, full-thickness penetrating keratoplasty has become a standard treatment for improving vision. Now more advanced surgical interventions such as deep anterior lamellar keratoplasty(DALK)and phototherapeutic keratectomy(PTK)have also been shown to be important in the treatment of MCD. Some new technologies, such as gene targeting therapy and enzyme replacement therapy, are also being studied as potential permanent solutions for MCD. The pathogenesis, genetic basis, clinical manifestations, treatment and prognosis of this disease are reviewed in this paper.
- Full text:201911012.pdf
